(Circulation. 1995;92:3089-3093.)
© 1995 American Heart Association, Inc.
Articles |
Epinephrine Increases the Severity of Postresuscitation Myocardial Dysfunction
From the Institute of Critical Care Medicine, Palm Springs, Calif.
Correspondence to Max Harry Weil, MD, PhD, Institute of Critical Care Medicine, 1695 North Sunrise Way, Palm Springs, CA 92262.
 |
Abstract |
|---|
 Top Abstract IntroductionMethods Results Discussion References |
|---|
Background Epinephrine has been the mainstay for cardiac resuscitation for more than 30 years. Its vasopressor effect by which it increases coronary perfusion pressure is likely to favor initial resuscitation. Its ß-adrenergic action, however, may have detrimental effects on postresuscitation myocardial function when administered before resuscitation because it increases myocardial oxygen consumption. In the present study, our focus was on postresuscitation effects of epinephrine when this adrenergic agent was administered during cardiopulmonary resuscitation. Postresuscitation myocardial functions were compared with those of a selective
-adrenergic agent,
phenylephrine, when epinephrine was combined with a
ß1-adrenergic blocking agent, esmolol, and saline
placebo.
Methods and Results Ventricular fibrillation was
induced in 40 Sprague-Dawley rats. Mechanical ventilation and
precordial compression was initiated either 4 or 8 minutes
after the start of ventricular fibrillation. The adrenergic
drug or saline placebo was administered as a bolus after 4 minutes of
precordial compression. Defibrillation was attempted 4 minutes
later. Left ventricular pressure,
dP/dt40, and negative dP/dt were continuously
measured for an interval of 240 minutes after successful cardiac
resuscitation. Except for saline placebo, comparable increases in
coronary perfusion pressure were observed after each drug
intervention. The number of countershocks required for restoration of
spontaneous circulation was significantly greater for
epinephrine-treated animals (10±8) when compared with
phenylephrine-treated animals (1.8±0.4,
P<.01) and with animals treated with epinephrine
combined with esmolol (1.6±0.9, P<.01). After
resuscitation, dP/dt40 and negative dP/dt were
significantly decreased and left ventricular
end-diastolic pressure was significantly increased in
each animal when compared with prearrest levels. However, the greatest
impairment followed epinephrine, and this was associated with
significantly greater heart rate and the shortest interval of
postresuscitation survival of 8±4 hours, whereas placebo controls
survived for 12±11 hours. Phenylephrine-treated
animals survived for 41±10 hours (P<.01 versus
epinephrine), and animals that received a combination of
epinephrine and esmolol survived for 35±11 hours
(P<.01 versus epinephrine). When the duration of
untreated cardiac arrest was increased from 4 to 8 minutes, the
severity of postresuscitation left ventricular dysfunction
was magnified, but disproportionate decreases in postresuscitation
survival were again observed with placebo and epinephrine when
compared with -adrenergic agonists.
Conclusions In an established rodent model after resuscitation
following cardiac arrest, epinephrine significantly increased
the severity of postresuscitation myocardial dysfunction and decreased
duration of survival. More selective -adrenergic agonist or
blockade of ß1-adrenergic actions of epinephrine
reduced postresuscitation myocardial impairment and prolonged
survival.
Key Words: myocardium • cardiopulmonary resuscitation
|
Introduction |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Until recently, cardiac resuscitation research focused primarily on the success of the initial stage of cardiac resuscitation and therapeutic options by which a viable rhythm and spontaneous circulation would be restored. We have designated this stage as stage 1. However, experimental studies by our group have demonstrated substantial impairment of ventricular function after resuscitation from cardiac arrest, which accounted for a high incidence in postresuscitation fatalities. We have now designated this stage as stage 2.1 Indeed, postresuscitation myocardial dysfunction may explain, at least in part, the fatality rate (>30%) that has been documented in human patients within the first 72 hours after initially successful resuscitation from cardiac arrest.2 3
Epinephrine has been the preferred adrenergic amine for the
treatment of human cardiac arrest for almost 30
years.4 5 6 7 8 9
There is persuasive evidence that its efficacy is due to its
-adrenergic vasopressor effects. The ß-adrenergic actions,
however, are not of proven benefit. To the contrary, potential adverse
effects of epinephrine have been identified. These are likely
to be due to its ß-inotropic actions, which provoke
disproportionate increases in myocardial oxygen consumption and thereby
increase the severity of myocardial
ischemia.10 11 12
The present study was designed to examine whether these
ß-adrenergic effects of epinephrine, when administered
during cardiopulmonary resuscitation (CPR), adversely
affect postresuscitation myocardial function when compared with those
of a more selective -agonist, phenylephrine, and
when epinephrine was combined with a short-acting
ß1-adrenergic blocking agent. The duration of untreated
ventricular fibrillation and CPR before attempted
defibrillation was adjusted to secure the success of cardiac
resuscitation for the purpose of this study, which was with focus on
postresuscitation myocardial dysfunction.
|
Methods |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
All animals received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published by the National Institute of Health (NIH publication 86-32, revised 1985).
Preparation
The experiments were performed in a previously
described
rat model of cardiac arrest and cardiac resuscitation. This model has
provided cardiopulmonary and metabolic
measurements that are comparable to those documented in larger mammals
and human patients.13 14 Briefly, 40
Sprague-Dawley rats (450 to 570 g) were fasted overnight
except for free access to water. The animals were anesthetized
by intraperitoneal injection of 45 mg/kg
pentobarbital sodium supplemented with additional doses of 10 mg/kg at
hourly intervals, except that no pentobarbital was administered for 30
minutes before induction of cardiac arrest. The trachea was orally
intubated with a 14-gauge cannula (Quick-Cath, Vicra Division, Travenol
Laboratory) mounted on a blunt needle with a 145° angled tip. For
measurement of PETCO2, the
respiratory gas was sampled through a side manifold interposed between
the tracheal cannula and the respirator. The
PCO2 was measured with a side-stream
infrared CO2 analyzer (model 200, Instrumentation
Laboratories). For measurement of left ventricular pressure
and both dP/dt40 and negative dP/dt, a Teflon catheter (UTX
022; internal diameter, 0.6 mm; outer diameter, 0.97 mm; length, 8 cm;
Becton Dickinson) was advanced into the left ventricle from the right
carotid artery. Through the left external jugular vein, an 18-gauge
polyethylene catheter (CPMS-401J-Fa, Cook) was advanced through the
superior vena cava into the right ventricle. Guided by pressure
monitoring, the catheter was slowly withdrawn into the right atrium.
Right atrial pressure was measured with reference to the midchest with
a high-sensitivity transducer (P-23-9b, Spectramed). This catheter
was also used to sample blood from the right atrium. Through the right
external jugular vein, a 3F pediatric radial artery catheter (model
C-PUM-301J, Cook) was advanced into the right atrium. A precurved guide
wire supplied with the catheter was then advanced through the catheter
into the right ventricle until an endocardial ECG was observed. Through
the right femoral artery, a Teflon catheter (UTX 022, Becton Dickinson)
was advanced into the thoracic aorta for measurement of aortic pressure
with a model TNF-R transducer (Abbott Critical Care). Through the left
femoral artery and left femoral vein, catheters (UTX 022, Becton
Dickinson) were advanced into the abdominal aorta and
inferior vena cava for sampling arterial blood
and blood replacement. Rectal temperature was measured continuously
with a rectal thermistor. Conventional lead II ECGs were recorded
with skin electrodes (model E220, In-vivo Metric).
Experimental Procedure
Experiments were performed in two
groups of animals. In group 1,
the duration of untreated ventricular fibrillation (VF) was
4 minutes; in group 2, the duration of untreated VF was 8 minutes.
Accordingly, the study was performed in 8 subsets of animals. The
investigators were blinded to the intervention until immediately before
induction of VF, at which time the principal investigator opened a
sealed envelope, the contents of which provided for randomization of
the animal to receive either epinephrine,
phenylephrine, epinephrine with esmolol, or saline
placebo.
The tracheal tube was connected to a volume-controlled ventilator as previously described.13 14 Ventilation was initially established at a tidal volume of 0.65 mL/100 g animal weight and a frequency of 100 breaths per minute 15 minutes before induction of cardiac arrest. The tidal volume was then adjusted to compensate for the volume of gas sampled by the CO2 analyzer to maintain PETCO2 between 30 and 35 mm Hg. The inspired O2 fraction (FIO2) was 1.0. A progressive increase in 60-Hz current to a maximum of 8 mA was then delivered to the right ventricular endocardium, and current flow was continued for 3 minutes. Mechanical ventilation was discontinued immediately after induction of VF. Either 4 or 8 minutes after onset of VF, precordial compression was initiated and continued for 8 minutes with a pneumatically driven mechanical chest compressor. Compression was maintained at a rate of 200 · min-1 with equal compression-relaxation duration (ie, 50% duty cycle). Compression depth was equivalent to 30% of the anteroposterior diameter of the chest and was adjusted to maintain coronary perfusion pressure (CPP) at 25 to 30 mm Hg. Coincident with the start of precordial compression, mechanical ventilation was resumed. Compression and ventilation were synchronized to maintain two compressions for each ventilation.
After 4 minutes of precordial compression, 0.2 mL of either epinephrine (30 µg/kg), phenylephrine (300 µg/kg), epinephrine with esmolol (30 µg + 300 µg/kg), or 0.9N NaCl solution (saline placebo) was bolus injected into the right atrium. After 8 minutes of precordial compression, a 2-J DC countershock was delivered between the anterior chest and the back. If VF was not reversed within 2 seconds, a second 2-J DC countershock was delivered. In unsuccessfully resuscitated animals, precordial compression was then resumed for 30 seconds before delivery of a second sequence of countershocks. Resuscitated animals were monitored for an additional 4 hours. One hour after successful resuscitation, each of the resuscitated animals was reanesthetized with pentobarbital in doses of 10 mg/mg. These doses were repeated at hourly intervals thereafter for a total of 4 doses. All catheters including the endotracheal tube were then removed. The animals were then observed for a total of 48 hours, after which they were euthanized by intraperitoneal injection of pentobarbital (150 mg/kg). Autopsy was routinely performed to identify adverse effects of the interventions and especially traumatic injuries of thoracic and/or abdominal organs.
Measurements
A 2-mL bolus of arterial blood from a donor
rat of the same colony was transfused into the inferior
vena cava 30 seconds before withdrawal of 1 mL aliquots of blood each
from the aorta and the right atrium.
PO2,
PCO2, and lactic acid were measured on
these samples by techniques previously described.15 At 1
and 7 minutes of precordial compression and at 5, 30, 60, 120,
180, and 240 minutes after resuscitation, these measurements were
repeated. Aortic, left ventricular, and right atrial
pressures, ECG, and PETCO2 were
continuously monitored on a six-channel recorder (model 2600,
Gould Inc) and recorded on a PC-based data acquisition system
supported by CODAS software. The CPP was calculated as
the difference between decompression diastolic aortic and
time-coincident right atrial pressure measured at the end of each
minute of precordial compression.
Myocardial function was assessed from measurements of left ventricular pressure. The rate of left ventricular pressure increase was measured at a left ventricular pressure of 40 mm Hg (dP/dt40) as indicative of isovolemic contractility.16 17 The rate of left ventricular pressure decline (-dP/dt) was measured as an estimate of myocardial relaxation. These were measured by analog differentiation of the left ventricular pressure. The frequency response of the system was 35 Hz with optimal damping.
Statistical Analysis
For measurements between groups, ANOVA
and
Scheffé's multicomparison techniques were used. Comparisons
between time-based measurements within each group were performed
with ANOVA repeated measurements. The outcome differences were
analyzed with Fisher's exact test. Measurements are reported
as mean±SD. A value of P<.05 was considered
significant.
|
Results |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Baseline hemodynamic and blood analytical measurements did not differ significantly among the eight subsets. There were no differences in aortic systolic pressure and blood gas measurements between groups during CPR and after successful resuscitation. After intra-atrial injection of epinephrine, CPP increased from 25±2 to 35±4 mm Hg (P<.01). Comparable increases in CPP were observed with phenylephrine (26±1 to 37±2 mm Hg, P<.01) and with the epinephrine-esmolol combination (24±2 to 33±3 mm Hg). There was no increase in CPP after intra-atrial injection of placebo. Increases in CPP after injection of each of the adrenergic drugs in the subsets in which untreated VF was prolonged to 8 minutes were approximately the same. All animals treated with adrenergic agents were successfully resuscitated with transthoracic countershock. After saline placebo, 4 of 5 animals were successfully resuscitated when untreated VF was of 4-minute duration and 3 of 5 when it was of 8-minute duration (Table
). The duration of survival after successful
resuscitation was significantly decreased in
epinephrine-treated and placebo-treated animals when
compared with phenylephrine-treated and
epinephrine-esmolol–treated animals after 4 or 8
minutes of untreated VF. The total energy required for successful
defibrillation after both 4 and 8 minutes was significantly greater in
placebo-treated animals (P<.01) and
epinephrine-treated animals (P<.01) when
compared with animals treated with phenylephrine or
epinephrine-esmolol.
|
As previously observed by us,1 myocardial
contractility as measured by dP/dt40 was
significantly decreased in all animals after successful resuscitation.
When the duration of untreated cardiac arrest was increased from 4 to 8
minutes, such decreases in dP/dt40 were magnified.
However, the greatest impairment of myocardial
contractility followed treatment with
epinephrine (Fig 1). The decreases in negative
dP/dt (Fig 2), the increases in left
ventricular end-diastolic pressure (Fig 3), and heart rate (Fig
4) also were
magnified after placebo and after epinephrine.
|
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
The present study demonstrated that in this rat model of cardiac arrest and resuscitation, the reversal of global myocardial ischemia after cardiac resuscitation is followed by myocardial dysfunction. Its severity is increased with increasing duration of untreated cardiac arrest. Epinephrine significantly increases the severity of postresuscitation myocardial dysfunction with consequent reduction in duration of postresuscitation survival when compared with the selective
-agonist phenylephrine
and after epinephrine was combined with the
ß1-blocking agent esmolol. We also observed that
epinephrine-treated animals required a larger number of
electrical countershocks before successful conversion to a viable
rhythm and restoration of spontaneous circulation. The doses of epinephrine were empirically established by earlier trials such as to ensure that it resulted in increased coronary perfusion pressure to minimal levels of 30 mm Hg. This yielded both a sufficiently severe global ischemic insult to the heart and consequently substantial postresuscitation contractile dysfunction, yet with 95% resuscitability.
In 1906, Crile and Dolley18 demonstrated that
epinephrine restored spontaneous circulation in a dog model
when cardiac arrest was induced by asphyxia. During the 1960s, Redding
and Pearson19 20 21 22
reexamined the effects of
epinephrine together with those of selective -agonist,
methoxamine, in the same setting of asphyxia-induced VF in
dogs. They observed greater success when a more selective
-adrenergic amine was administered. More recently, Roberts et
al23 compared the effects of a pure -agonist,
methoxamine, and epinephrine on myocardial and cerebral
blood flow during CPR in dogs. They found that methoxamine
produced significantly greater myocardial and cerebral blood flow
during precordial compression. This was associated with
significantly improved postresuscitation cardiac output and survival
when compared with epinephrine. These experimental observations
have not yet affected the American Heart Association Guidelines for
CPR, in which epinephrine remains as the adrenergic agent of
first choice.5 6 7 Moreover, there is
currently little
distinction between the benefits and detriments of adrenergic
vasopressor drugs in clinical settings of sudden death due to cardiac
cause and the much smaller incidence of cardiac arrest due to
noncardiac causes including asphyxiation. The present study uses a
model in which a primary cardiac insult is induced.
The mechanism by which epinephrine administered during
CPR increases the severity of postresuscitation myocardial dysfunction
after primary VF was initially suggested by Ditchey and
Lindenfeld.11 These investigators pointed to its ß
effects, by which the myocardial oxygen requirement was increased.
During cardiac resuscitation in dogs, a bolus injection of 1 mg of
epinephrine followed by continuous infusion of 0.2 mg/min over
an interval of 10 minutes increased myocardial lactate content and
decreased myocardial ATP content even though coronary blood
flow was doubled. Comparable increases in myocardial blood flow that
followed infusion of a more selective 1-agonist,
methoxamine, were not accompanied by such increases in the
oxygen consumption.10 The importance of distinguishing
between benefits and detriments of ß-agonists was emphasized by
Halperin and Guerci.12 The normal balance of myocardial
energy supply and demand is disrupted during VF because the demand of
the myocardium for energy exceeds that which is available
from a reserve of high-energy phosphates and from
anaerobic glycolysis. Consequently, the net supply of ATP
available to the myocyte decreases to a critical
level.24 25 Decreases in myocardial tissue ATP during
ischemia are correlated with the severity of myocardial injury
and therefore predictive of myocyte survival when coronary
perfusion is restored.26 27 28
Equally important, the severity of postresuscitation myocardial dysfunction was significantly reduced in the present studies when epinephrine was administered in combination with esmolol. Since esmolol blocked ß1-adrenergic receptors, it would be likely to decrease the oxygen requirements of the myocardium during VF and thereby minimize global ischemic injury. Ditchey et al29 had earlier presented experimental evidence in dogs that both resuscitability and postresuscitation myocardial function were improved after nonspecific ß-adrenergic blockade with propranolol. In their studies, coronary perfusion pressure was augmented when epinephrine was combined with propanolol. In the present study, in which epinephrine was combined with a more selective ß1-adrenergic blocking agent, this effect was not apparent. This would further support the hypothesis proposed by Ditchey et al29 in that ß2-blockade may have accounted for the increases in CPP reported by them. Additional evidence that epinephrine has unfavorable postresuscitation cardiovascular effects was published by Berg et al.30 In a pig model of CPR, high doses of epinephrine (0.2 mL/kg) administered during CPR were followed by postresuscitation tachycardia and a substantial increase in early mortality.
In the present study, we also observed that epinephrine-treated animals required a larger number of electrical countershocks for conversion of VF to a regular rhythm. This was consistent with earlier reports by Niemann and his associates31 and by Wright et al,32 which provided evidence that the ß-adrenergic actions of epinephrine increased the severity of myocardial ischemic injury and thereby the likelihood of reentrant and ectopic ventricular dysrhythmias.31 32
We conclude that epinephrine, when administered during CPR under the experimental conditions of this and predecessor studies in other species, significantly increases the severity of postresuscitation myocardial dysfunction in consequence of its ß1-adrenergic actions. This is associated with significantly greater postresuscitation mortality. It would be appropriate to reevaluate epinephrine as the drug of first choice for cardiac resuscitation after "sudden death."
|
Acknowledgments |
|---|
This study was supported in part by an American Heart Association Grant-in-Aid and the Laerdal Foundation for Acute Medicine, Inc, Stavanger, Norway.
Received March 6, 1995; revision received May 29, 1995; accepted July 5, 1995.
|
References |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
1. Tang W, Weil MH, Sun SJ, Gazmuri RJ, Bisera J. Progressive myocardial dysfunction after cardiac resuscitation. Crit Care Med. 1993;21:1046-1050. [Medline] [Order article via Infotrieve]
2. Liberthson RR, Negal EL, Hirschman JC, Nussenfeld SR. Prehospital ventricular defibrillation: prognosis and follow-up course. N Engl J Med. 1974-291:317-321.
3. Brown CG, Martin DR, Pepe P, Smeven H, Cummins R, Gonzalez E, Jastremaki M, and the Multicenter High-Dose Epinephrine Study Group. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. N Engl J Med. 1992;327:1051-1055. [Abstract]
4.
Lewis CM, Weil MH. Hemodynamic
spectrum of vasopressor and vasodilator drugs. JAMA. 1969;208:1391-1398.
5.
Standards and guidelines for
cardiopulmonary resuscitation (CPR) and emergency cardiac
care (ECC). JAMA. 1980;244:453-509.
6.
Standards and guidelines for
cardiopulmonary resuscitation (CPR) and emergency cardiac
care (ECC). JAMA. 1986;255:2905-2989.
7.
Guidelines for cardiopulmonary
resuscitation and emergency cardiac care. JAMA. 1992;268:2184-2241.
8. Otto CW, Yakaitis RW. The role of epinephrine in CPR: a reappraisal. Ann Emerg Med. 1984;13:840-843. [Medline] [Order article via Infotrieve]
9. Robinson LA, Brown CG, Jenkins J, Van Ligten PF, Werman H, Ashton J, Hamlin RL. The effect of norepinephrine versus epinephrine on myocardial hemodynamics during CPR. Ann Emerg Med. 1989;18:336-340. [Medline] [Order article via Infotrieve]
10. Livesay JJ, Follette DML, Fey KH, Nelson RL, Deland EC, Barnard RJ, Buckberg GD. Optimizing myocardial supply/demand balance with alpha-adrenergic drugs during cardiopulmonary resuscitation. J Thorac Cardiovasc Surg. 1978;76:244-251. [Abstract]
11.
Ditchey RV, Lindenfeld J. Failure of
epinephrine to improve the balance between myocardial oxygen
supply and demand during closed-chest resuscitation in
dogs. Circulation. 1988;78:382-389.
12. Halperin HR, Guerci AD. Vasoconstrictors during CPR. Are they used optimally? Chest. 1990;97:787-789.
13.
von Planta I, Weil MH, von Planta M, Bisera J, Bruno S,
Gazmuri RJ, Rackow EC. Cardiopulmonary resuscitation
in the rat. J Appl Physiol. 1988;65:2641-2647.
14.
Tang W, Weil MH, Gazmuri RJ, Sun S, Duggal C, Bisera J.
Pulmonary ventilation/perfusion defects induced by
epinephrine during cardiopulmonary
resuscitation. Circulation. 1991;84:2101-2107.
15. Weil MH, Michaels S, Puri VK, Carlson W. The Stat laboratory: facilitating blood gas and biochemical measurements for the critically ill and injured. Am J Clin Pathol. 1981;76:34-42. [Medline] [Order article via Infotrieve]
16.
Mason DT, Braunwald E, Covell JW, Sonnenblick EH, Ross
J Jr. Assessment of cardiac contractility: the
relation between the rate of pressure rise and ventricular
pressure during isovolumic systole.
Circulation. 1971;44:47-58.
17. Carroll JD, Hess OM, Hirzel HO, Turina MT, Krayenbuehl MP. Effects of ischemia, bypass surgery and post-infarction on myocardial contraction, relaxation and compliance during exercise. Am J Cardiol. 1989;63:65E-71E. [Medline] [Order article via Infotrieve]
18. Crile G, Dolley DH. Experimental research into resuscitation of dogs killed by anaesthetic and asphyxia. J Exp Med. 1906;8:713-720.
19. Redding JS, Pearson JW. Evaluation of drugs for cardiac resuscitation. Anaesthesia. 1963;24:203-207.
20.
Redding JS, Pearson JW. Resuscitation from
ventricular fibrillation. JAMA. 1968;203:255-260.
21.
Pearson JW, Redding JS. Influence of
peripheral vascular tone on cardiac resuscitation.
Anesth Analg. 1965;44:746-752.
22. Pearson JW, Redding JS. The role of epinephrine in cardiac resuscitation. Anesth Analg. 1963;42:599-606.
23.
Roberts D, Landolfo K, Dobson K, Light BR. The
effects of methoxamine and epinephrine on survival and
regional distribution of cardiac output in dogs with prolonged
ventricular fibrillation. Chest. 1990;98:999-1005.
24. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol. 1974;36:413-459. [Medline] [Order article via Infotrieve]
25. Humphrey SM, Gavin JB, Herdson PB. Catecholamine-depletion and the no-flow phenomenon in anoxic and ischemic rat hearts. J Mol Cell Cardiol. 1982;14:151-161. [Medline] [Order article via Infotrieve]
26.
Jennings RB, Schaper J, Hill ML, Steenbergen C Jr,
Reimer KA. Effect of reperfusion late in the phase of reversible
ischemic injury: changes in cell volume, electrolytes,
metabolites, and ultrastructure. Circ Res. 1985;56:262-278.
27. Jennings RB, Reimer KA, Steenbergen C Jr. Myocardial ischemia revisited: the osmolar load, membrane damage and reperfusion. J Mol Cell Cardiol. 1986;18:769-780. [Medline] [Order article via Infotrieve]
28.
Reimer KA, Jennings RB, Hill ML. Total
myocardial ischemia in vitro: high-energy phosphate
depletion and associated defects in energy metabolism, cell
volume regulation, and sarcolemmal integrity.
Circ Res. 1981;49:901-911.
29. Ditchey RV, Rubio-Perez A, Slinker BK. Beta-adrenergic blockade reduces myocardial injury during experimental cardiopulmonary resuscitation. J Am Coll Cardiol. 1994;24:804-812. [Abstract]
30. Berg RA, Otto CW, Kern KB, Sanders AB, Hilwig RW, Hansen KK, Ewy GA. High-dose epinephrine results in greater early mortality after resuscitation from prolonged cardiac arrest in pigs: a prospective, randomized study. Crit Care Med. 1994;22:282-290. [Medline] [Order article via Infotrieve]
31. Niemann JT, Haynes KS, Garner D, Renni CJ III, Jagels G, Stormo O. Post-countershock pulseless rhythms: response to CPR, artificial cardiac pacing, and adrenergic agonists. Ann Emerg Med. 1986;15:112-120. [Medline] [Order article via Infotrieve]
32. Wright M, Heath RB, Wingfield WE. Effects of xylazine and ketamine on epinephrine-induced arrhythmia in the dog. Vet Surg. 1986;16:398-403.
This article has been cited by other articles:
 |
|
 |
|
  M. Harvey, G. Cave, and A. Kazemi Intralipid Infusion Diminishes Return of Spontaneous Circulation After Hypoxic Cardiac Arrest in Rabbits Anesth. Analg., April 1, 2009; 108(4): 1163 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schneider, B. W. Bottiger, and E. Popp Cerebral Resuscitation After Cardiocirculatory Arrest Anesth. Analg., March 1, 2009; 108(3): 971 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Burst Stimulation Improves Hemodynamics During Resuscitation after Prolonged Ventricular Fibrillation. Circ Arrhythm Electrophysiol, January 1, 2009; 2: 57 - 62.
|
|
|
|
 |
|
 P. J. Zed, R. B. Abu-Laban, M. Shuster, R. S. Green, R. S. Slavik, and A. H. Travers Update on cardiopulmonary resuscitation and emergency cardiovascular care guidelines Am. J. Health Syst. Pharm., December 15, 2008; 65(24): 2337 - 2346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Papadimitriou, T Xanthos, I Dontas, P Lelovas, and D Perrea The use of mice and rats as animal models for cardiopulmonary resuscitation research Lab Anim, July 1, 2008; 42(3): 265 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Simpson, K. R. Brunt, and S. Iscoe Repeated inspiratory occlusions acutely impair myocardial function in rats J. Physiol., May 1, 2008; 586(9): 2345 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Gonzalez, R. A. Berg, V. M. Nadkarni, C. B. Vianna, K. B. Kern, S. Timerman, and J. A. Ramires Left Ventricular Systolic Function and Outcome After In-Hospital Cardiac Arrest Circulation, April 8, 2008; 117(14): 1864 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Ferraris, F. H. Edwards, D. M. Shahian, and S. P. Ferraris Risk Stratification and Comorbidity Card. Surg. Adult, January 1, 2008; 3(2008): 199 - 246. [Full Text]
|
|
|
|
 |
|
 G. Ristagno, W. Tang, Y.-T. Chang, D. B. Jorgenson, J. K. Russell, L. Huang, T. Wang, S. Sun, and M. H. Weil The Quality of Chest Compressions During Cardiopulmonary Resuscitation Overrides Importance of Timing of Defibrillation Chest, July 1, 2007; 132(1): 70 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Fang, W. Tang, S. Sun, L. Huang, Y.-T. Chang, Z. Huang, and M. H. Weil Cardiopulmonary resuscitation in a rat model of chronic myocardial ischemia J Appl Physiol, October 1, 2006; 101(4): 1091 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 American Heart Association 2005 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) of Pediatric and Neonatal Patients: Pediatric Advanced Life Support Pediatrics, May 1, 2006; 117(5): e1005 - e1028. [Full Text] [PDF]
|
|
|
|
 |
|
 G. A.A.M. Cammarata, M. H. Weil, S. Sun, L. Huang, X. Fang, and W. Tang Levosimendan Improves Cardiopulmonary Resuscitation and Survival by KATP Channel Activation J. Am. Coll. Cardiol., March 7, 2006; 47(5): 1083 - 1085. [Full Text] [PDF]
|
|
|
|
|
|
C. L. McCaul, P. J. McNamara, D. Engelberts, G. J. Wilson, A. Romaschin, A. N. Redington, and B. P. Kavanagh Epinephrine Increases Mortality after Brief Asphyxial Cardiac Arrest in an In Vivo Rat Model Anesth. Analg., February 1, 2006; 102(2): 542 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Part 7.2: Management of Cardiac Arrest Circulation, December 13, 2005; 112(24_suppl): IV-58 - IV-66. [Full Text] [PDF]
|
|
|
|
|
|
Part 12: Pediatric Advanced Life Support Circulation, December 13, 2005; 112(24_suppl): IV-167 - IV-187. [Full Text] [PDF]
|
|
|
|
|
|
A. A. El-Menyar The Resuscitation Outcome: Revisit the Story of the Stony Heart Chest, October 1, 2005; 128(4): 2835 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Huang, M. H. Weil, S. Sun, W. Tang, and X. Fang Carvedilol Mitigates Adverse Effects of Epinephrine During Cardiopulmonary Resuscitation Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 113 - 120. [Abstract] [PDF]
|
|
|
|
|
|
J. Kolarova, Z. Yi, I. M. Ayoub, and R. J. Gazmuri Cariporide Potentiates the Effects of Epinephrine and Vasopressin by Nonvascular Mechanisms During Closed-Chest Resuscitation Chest, April 1, 2005; 127(4): 1327 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sun, M. H. Weil, W. Tang, T. Kamohara, and K. Klouche {delta}-Opioid receptor agonist reduces severity of postresuscitation myocardial dysfunction Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H969 - H974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Dyke II and J. D. Tobias Vasopressin: Applications in Clinical Practice J Intensive Care Med, July 1, 2004; 19(4): 220 - 228. [Abstract] [PDF]
|
|
|
|
|
|
C. R. Killingsworth, C.-C. Wei, L. J. Dell'Italia, J. L. Ardell, M. A. Kingsley, W. M. Smith, R. E. Ideker, and G. P. Walcott Short-Acting {beta}-Adrenergic Antagonist Esmolol Given at Reperfusion Improves Survival After Prolonged Ventricular Fibrillation Circulation, May 25, 2004; 109(20): 2469 - 2474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Tang, M. H. Weil, S. Sun, D. Jorgenson, C. Morgan, K. Klouche, and D. Snyder The effects of biphasic waveform design on post-resuscitation myocardial function J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1228 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Niemann, D. Garner, E. Khaleeli, and R. J. Lewis Milrinone Facilitates Resuscitation From Cardiac Arrest and Attenuates Postresuscitation Myocardial Dysfunction Circulation, December 16, 2003; 108(24): 3031 - 3035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pellis, M. H. Weil, W. Tang, S. Sun, J. Xie, L. Song, and P. Checchia Evidence Favoring the Use of an {alpha}2-Selective Vasopressor Agent for Cardiopulmonary Resuscitation Circulation, November 25, 2003; 108(21): 2716 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ji, B. Li, T. D. Reed, J. N. Lorenz, M. A. Kaetzel, and J. R. Dedman Targeted Inhibition of Ca2+/Calmodulin-dependent Protein Kinase II in Cardiac Longitudinal Sarcoplasmic Reticulum Results in Decreased Phospholamban Phosphorylation at Threonine 17 J. Biol. Chem., June 27, 2003; 278(27): 25063 - 25071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cao, M. H. Weil, S. Sun, and W. Tang Vasopressor Agents for Cardiopulmonary Resuscitation Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 115 - 121. [Abstract] [PDF]
|
|
|
|
|
|
L. Song, M. H. Weil, W. Tang, S. Sun, and T. Pellis Cardiopulmonary resuscitation in the mouse J Appl Physiol, October 1, 2002; 93(4): 1222 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Klouche, M. H. Weil, S. Sun, W. Tang, H. P. Povoas, T. Kamohara, and J. Bisera Evolution of the Stone Heart After Prolonged Cardiac Arrest* Chest, September 1, 2002; 122(3): 1006 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Sanoski ACLS Guidelines 2000: Focus on What's "New" in the Pulseless Ventricular Tachycardia/Ventricular Fibrillation Algorithm Journal of Pharmacy Practice, August 1, 2002; 15(4): 334 - 343. [Abstract] [PDF]
|
|
|
|
 |
|
 T. KAMOHARA, M. H. WEIL, W. TANG, S. SUN, H. YAMAGUCHI, K. KLOUCHE, and J. BISERA A Comparison of Myocardial Function after Primary Cardiac and Primary Asphyxial Cardiac Arrest Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1221 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Tang, M. H. Weil, S. Sun, H. P. Povoas, K. Klouche, T. Kamohara, and J. Bisera A Comparison of Biphasic and Monophasic Waveform Defibrillation After Prolonged Ventricular Fibrillation Chest, September 1, 2001; 120(3): 948 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Lurie, W. G. Voelckel, T. Zielinski, S. McKnite, P. Lindstrom, C. Peterson, V. Wenzel, K. H. Lindner, N. Samniah, and D. Benditt Improving Standard Cardiopulmonary Resuscitation with an Inspiratory Impedance Threshold Valve in a Porcine Model of Cardiac Arrest Anesth. Analg., September 1, 2001; 93(3): 649 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Krismer, Q. H. Hogan, V. Wenzel, K. H. Lindner, U. Achleitner, S. Oroszy, B. Rainer, A. Wihaidi, V. D. Mayr, P. Spencker, et al. The Efficacy of Epinephrine or Vasopressin for Resuscitation During Epidural Anesthesia Anesth. Analg., September 1, 2001; 93(3): 734 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Wenzel and K. H. Lindner Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor Cardiovasc Res, August 15, 2001; 51(3): 529 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sun, M. H. Weil, W. Tang, T. Kamohara, and K. Klouche Alpha-methylnorepinephrine, a selective alpha2-adrenergic agonist for cardiac resuscitation J. Am. Coll. Cardiol., March 1, 2001; 37(3): 951 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Niermeyer, W. Carlo, D. Boyle, J. Goldsmith, B. Nightengale, J. Perlman, A. Solimano, M. Speer, and T. Wiswell What Is on the Horizon for Neonatal Resuscitation? NeoReviews, February 1, 2001; 2(2): e51 - 57. [Full Text]
|
|
|
|
|
|
W. Tang, M. H. Weil, S. Sun, A. Pernat, and E. Mason KATP channel activation reduces the severity of postresuscitation myocardial dysfunction Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1609 - H1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Niemann, D. Burian, D. Garner, and R. J. Lewis Monophasic versus biphasic transthoracic countershock after prolonged ventricular fibrillation in a swine model J. Am. Coll. Cardiol., September 1, 2000; 36(3): 932 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Hilwig, R. A. Berg, K. B. Kern, and G. A. Ewy Endothelin-1 Vasoconstriction During Swine Cardiopulmonary Resuscitation Improves Coronary Perfusion Pressures but Worsens Postresuscitation Outcome Circulation, May 2, 2000; 101(17): 2097 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Wenzel, K. H. Lindner, A. C. Krismer, W. G. Voelckel, M. F. Schocke, W. Hund, M. Witkiewicz, E. A. Miller, G.u. Klima, J.o. Wissel, et al. Survival with full neurologic recovery and no cerebral pathology after prolonged cardiopulmonary resuscitation with vasopressin in pigs J. Am. Coll. Cardiol., February 1, 2000; 35(2): 527 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sun, M. H. Weil, W. Tang, H. P. Povoas, and E. Mason Combined Effects of Buffer and Adrenergic Agents on Postresuscitation Myocardial Function J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 773 - 777. [Abstract] [Full Text]
|
|
|
|
|
|
W. Tang, M. H. Weil, S. Sun, H. Yamaguchi, H. P. Povoas, A. M. Pernat, and J. Bisera The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function J. Am. Coll. Cardiol., September 1, 1999; 34(3): 815 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Wenzel, K. H. Lindner, A. C. Krismer, E. A. Miller, W. G. Voelckel, and W. Lingnau Repeated Administration of Vasopressin but Not Epinephrine Maintains Coronary Perfusion Pressure After Early and Late Administration During Prolonged Cardiopulmonary Resuscitation in Pigs Circulation, March 16, 1999; 99(10): 1379 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Wenzel, K. H. Lindner, S. Augenstein, A. W. Prengel, H. U. Strohmenger, and R. C. Koehler Vasopressin Combined With Epinephrine Decreases Cerebral Perfusion Compared With Vasopressin Alone During Cardiopulmonary Resuscitation in Pigs • Editorial Comment Stroke, July 1, 1998; 29(7): 1462 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Advanced Life Support Working Group of the Europea The 1998 European Resuscitation Council guidelines for adult advanced life support BMJ, June 20, 1998; 316(7148): 1863 - 1869. [Full Text]
|
|
|
|
|
|
J. Xie, M. H. Weil, S. Sun, W. Tang, Y. Sato, X. Jin, and J. Bisera High-Energy Defibrillation Increases the Severity of Postresuscitation Myocardial Dysfunction Circulation, July 15, 1997; 96(2): 683 - 688. [Abstract] [Full Text]
|
|
|
|
|
|
K. B. Kern, R. W. Hilwig, R. A. Berg, K. H. Rhee, A. B. Sanders, C. W. Otto, and G. A. Ewy Postresuscitation Left Ventricular Systolic and Diastolic Dysfunction : Treatment With Dobutamine Circulation, June 17, 1997; 95(12): 2610 - 2613. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. H. Weil, W. Tang, S. Sun, and J. Bisera Cardiopulmonary Resuscitation and Survival Arch Intern Med, January 22, 1996; 156(2): 215 - 216. [Abstract] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||